{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:40Z","timestamp":1787019580867,"version":"build-2736575974"},"reference-count":44,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of B-cell malignancies, but similar success in T-cell and myeloid leukemias has remained elusive due to unique biological and logistical barriers. T-cell acute lymphoblastic leukemia poses challenges such as fratricide, product contamination, and profound immunosuppression from T-cell aplasia. Gene editing, protein expression blockers, and antigen selection strategies have been employed to mitigate these risks, while allogeneic CAR T-cell platforms offer rapid deployment but carry risks of graft-versus-host disease and immune rejection. Early-phase trials targeting CD5 and CD7 have demonstrated promising response rates, particularly with gene-edited or bicistronic constructs, although toxicities and the need for consolidative hematopoietic stem cell transplantation remain significant hurdles. Similarly, CAR T-cell therapy for acute myeloid leukemia faces the dual obstacles of antigen nonspecificity and a highly immunosuppressive tumor microenvironment. Multiantigen targeting, logic-gated designs, and epitope editing have emerged to improve specificity and safety. Novel approaches to overcome the immunosuppressive milieu include checkpoint blockade and cytokine pathway modulation. Allogeneic and \u201coff-the-shelf\u201d CAR T-cell products are being developed to address manufacturing challenges in patients with rapidly progressive disease. Collectively, these advances highlight the potential of cellular therapies in high-risk leukemias and underscore the importance of continued innovation to improve outcomes in these historically treatment-refractory populations. Using a real-world case, we highlight the major challenges and innovative strategies shaping CAR T-cell therapy for T-cell acute lymphoblastic leukemia and acute myeloid leukemia.<\/jats:p>","DOI":"10.1182\/hematology.2025000733","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:09:02Z","timestamp":1764943742000},"page":"424-431","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Have CARs stalled for non\u2013B-cell malignancies? Where are we, and where are we going?"],"prefix":"10.1182","volume":"2025","author":[{"given":"Sara","family":"Silbert","sequence":"first","affiliation":[{"name":"1 Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Lamble","sequence":"additional","affiliation":[{"name":"2 Division of Hematology and Oncology, University of Washington, Seattle Children's Hospital, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"issue":"10","key":"2026012712165443000_hem2025000733C1","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"2026012712165443000_hem2025000733C2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10555-025-10261-7","article-title":"CAR T-cells for acute leukemias in children: current status, challenges, and future directions","volume":"44","author":"Dourthe","year":"2025","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"2026012712165443000_hem2025000733C3","doi-asserted-by":"crossref","first-page":"101628","DOI":"10.1016\/j.xcrm.2024.101628","article-title":"Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity","volume":"5","author":"Ma","year":"2024","journal-title":"Cell Rep Med"},{"issue":"21","key":"2026012712165443000_hem2025000733C4","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","article-title":"Fratricide- resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia","volume":"133","author":"S\u00e1nchez-Mart\u00ednez","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2026012712165443000_hem2025000733C5","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood.2025028387","article-title":"Phase 1\/2 trial of anti-CD7 allogeneic WU-CART-007 in patients with relapsed\/refractory T-cell malignancies","volume":"146","author":"Ghobadi","year":"2025","journal-title":"Blood"},{"issue":"10","key":"2026012712165443000_hem2025000733C6","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base- edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N Engl J Med"},{"issue":"30","key":"2026012712165443000_hem2025000733C7","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"25","key":"2026012712165443000_hem2025000733C8","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"2026012712165443000_hem2025000733C9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40164-022-00368-w","article-title":"The emerging scenario of immunotherapy for T-cell acute lymphoblastic leukemia: advances, challenges and future perspectives","volume":"12","author":"Caracciolo","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"2026012712165443000_hem2025000733C10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41591-024-03326-7","article-title":"TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1\/2 trial","volume":"31","author":"Cwynarski","year":"2025","journal-title":"Nat Med"},{"key":"2026012712165443000_hem2025000733C11","doi-asserted-by":"crossref","first-page":"780442","DOI":"10.3389\/fimmu.2021.780442","article-title":"T cell fitness and autologous CAR T cell therapy in haematologic malignancy","volume":"12","author":"Mehta","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"2026012712165443000_hem2025000733C12","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2022015825","article-title":"Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL","volume":"140","author":"Diorio","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2026012712165443000_hem2025000733C13","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1182\/blood.2022016052","article-title":"Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation","volume":"141","author":"Mo","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026012712165443000_hem2025000733C14","first-page":"64","article-title":"A novel CD7 chimeric antigen receptor- modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia","volume":"9","author":"You","year":"2019","journal-title":"Am J Cancer Res"},{"issue":"1","key":"2026012712165443000_hem2025000733C15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40164-023-00431-0","article-title":"Chimeric antigen receptor engineered natural killer cells for cancer therapy","volume":"12","author":"Zhang","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"14","key":"2026012712165443000_hem2025000733C16","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood.2023022920","article-title":"Classification and risk stratification in T-lineage acute lymphoblastic leukemia","volume":"145","author":"P\u00f6l\u00f6nen","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2026012712165443000_hem2025000733C17","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/bloodadvances.2023012263","article-title":"CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?","volume":"9","author":"Maciocia","year":"2025","journal-title":"Blood Adv"},{"issue":"13","key":"2026012712165443000_hem2025000733C18","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood.2023022204","article-title":"Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed\/refractory mature T-cell lymphomas","volume":"143","author":"Hill","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026012712165443000_hem2025000733C19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41591-024-03282-2","article-title":"Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial","volume":"31","author":"Pan","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"2026012712165443000_hem2025000733C20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","article-title":"Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia","volume":"16","author":"Tan","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2026012712165443000_hem2025000733C21","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","article-title":"Fratricide-resistant CD7-CAR T cells in T-ALL","volume":"30","author":"Oh","year":"2024","journal-title":"Nat Med"},{"issue":"16","key":"2026012712165443000_hem2025000733C22","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"2026012712165443000_hem2025000733C23","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood.2024024063","article-title":"Honing CAR T cells to tackle acute myeloid leukemia","volume":"145","author":"Haubner","year":"2025","journal-title":"Blood"},{"issue":"6","key":"2026012712165443000_hem2025000733C24","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.3324\/haematol.2023.283817","article-title":"Chimeric antigen receptor T-cell therapy in childhood acute myeloid leukemia: how far are we from a clinical application?","volume":"109","author":"Naik","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"2026012712165443000_hem2025000733C25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1158\/2643-3230.BCD-23-0258","article-title":"CD33-CD123 IF-THEN gating reduces toxicity while enhancing the specificity and memory phenotype of AML- targeting CAR-T cells","volume":"6","author":"Jambon","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2026012712165443000_hem2025000733C26","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","article-title":"Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia","volume":"12","author":"El Khawanky","year":"2021","journal-title":"Nat Commun"},{"issue":"5","key":"2026012712165443000_hem2025000733C27","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00428-024-03741-8","article-title":"Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents","volume":"485","author":"Marques-Piubelli","year":"2024","journal-title":"Virchows Arch"},{"issue":"9","key":"2026012712165443000_hem2025000733C28","doi-asserted-by":"crossref","first-page":"e162593","DOI":"10.1172\/JCI162593","article-title":"Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing","volume":"134","author":"Appelbaum","year":"2024","journal-title":"J Clin Invest"},{"issue":"5","key":"2026012712165443000_hem2025000733C29","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv"},{"key":"2026012712165443000_hem2025000733C30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.omto.2023.07.003","article-title":"Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells","volume":"30","author":"Magnani","year":"2023","journal-title":"Mol Ther Oncolytics"},{"issue":"10","key":"2026012712165443000_hem2025000733C31","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.ymthe.2020.06.022","article-title":"Allogeneic FLT3 CAR T cells with an off-switch exhibit potent activity against AML and can be depleted to expedite bone marrow recovery","volume":"28","author":"Sommer","year":"2020","journal-title":"Mol Ther"},{"issue":"23","key":"2026012712165443000_hem2025000733C32","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1182\/blood.2021010784","article-title":"Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity","volume":"137","author":"Foster","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2026012712165443000_hem2025000733C33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-024-01082-y","article-title":"Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control","volume":"14","author":"Lin","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026012712165443000_hem2025000733C34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","article-title":"Catch me if you can: how AML and its niche escape immunotherapy","volume":"36","author":"Tettamanti","year":"2022","journal-title":"Leukemia"},{"key":"2026012712165443000_hem2025000733C35","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fonc.2020.00262","article-title":"A bump in the road: how the hostile AML microenvironment affects CAR T Cell therapy","volume":"10","author":"Epperly","year":"2020","journal-title":"Front Oncol"},{"issue":"12","key":"2026012712165443000_hem2025000733C36","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood.2023022882","article-title":"Targeting of the CD161 inhibitory receptor enhances T-cell-mediated immunity against hematological malignancies","volume":"143","author":"Alvarez Calderon","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026012712165443000_hem2025000733C37","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3892\/mmr.2021.11847","article-title":"Cytotoxic effect of CLL-1 CAR-T cell immunotherapy with PD-1 silencing on relapsed\/refractory acute myeloid leukemia","volume":"23","author":"Lin","year":"2021","journal-title":"Mol Med Rep"},{"key":"2026012712165443000_hem2025000733C38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.canlet.2019.10.032","article-title":"Blocking migration of regulatory T cells to leukemic hematopoietic microenvironment delays disease progression in mouse leukemia model","volume":"469","author":"Wang","year":"2020","journal-title":"Cancer Lett"},{"issue":"12","key":"2026012712165443000_hem2025000733C39","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","article-title":"Cytokine-mediated CAR T therapy resistance in AML","volume":"30","author":"Bhagwat","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"2026012712165443000_hem2025000733C40","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2023-179667","article-title":"CD33 CAR T-cells (CD33CART) for children and young adults with relapsed\/refractory AML: dose-escalation results from a phase I\/II multicenter trial","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2026012712165443000_hem2025000733C41","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-6367(23)00184-7","article-title":"Preliminary results from a phase 1 trial showing safety and anti-leukemic activity of CD123-CAR T cells in pediatric patients with AML","volume":"29","author":"Naik","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"2026012712165443000_hem2025000733C42","doi-asserted-by":"crossref","first-page":"9655","DOI":"10.1002\/cam4.5916","article-title":"Anti-CLL1-based CAR T-cells with 4-1-BB or CD28\/CD27 stimulatory domains in treating childhood refractory\/relapsed acute myeloid leukemia","volume":"12","author":"Pei","year":"2023","journal-title":"Cancer Med"},{"issue":"11","key":"2026012712165443000_hem2025000733C43","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1038\/s41375-022-01703-0","article-title":"Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"2026012712165443000_hem2025000733C44","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","article-title":"CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial","volume":"10","author":"Sallman","year":"2023","journal-title":"Lancet Haematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/424\/2500936\/424silbert.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/424\/2500936\/424silbert.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T17:17:04Z","timestamp":1769534224000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/424\/556858\/Have-CARs-stalled-for-non-B-cell-malignancies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,2]]},"published-print":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000733","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,2]]},"published":{"date-parts":[[2025,12,2]]}}}